UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13D/A

(Rule 13d-101)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

 

(Amendment No. 10)[1]

 

 

Catalyst Biosciences, Inc.

(Name of Issuer)

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

  14888D208  
  (CUSIP Number)  

 

JULIAN D. SINGER

JDS1, LLC

2200 Fletcher Avenue, Suite 501

Fort Lee, New Jersey 07024

(201) 592-3400

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

 

  April 20, 2022  
(Date of Event which Requires Filing of this Statement) 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box 󠄀󠄠

 

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

 

[1]        The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP NO. 14888D208

 

1

NAME OF REPORTING PERSON

 

JDS1, LLC

     
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)

 

 

 

 

 

 

 

(b)

 

3

 

SEC USE ONLY

 

 

4

SOURCE OF FUNDS*

 

WC, AF
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

 

 

 

 
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

 

0
8

SHARED VOTING POWER

 

1,312,532
9

SOLE DISPOSITIVE POWER

 

0
10

SHARED DISPOSITIVE POWER

 

1,312,532
11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

1,312,532
12  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

 

 

 
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

4.17%[2]
14  TYPE OF REPORTING PERSON*
OO

 

 

[2]       The aggregate percentage of shares of Common Stock reported as owned by each Reporting Person is based upon 31,477,053 shares of Common Stock outstanding, which is the total number of Shares outstanding as of March 25, 2022, as reported in the Issuer’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 31, 2022.

 

 

CUSIP NO. 14888D208

 

1

 NAME OF REPORTING PERSON

 

CCUR Holdings, Inc.

       
2  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)

 

 

 

 

 

 

 

 

(b)

 

 
3

SEC USE ONLY

 

 

 
4

SOURCE OF FUNDS*

 

 
WC  
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

 

 

 

 
   
6 CITIZENSHIP OR PLACE OF ORGANIZATION  
Delaware  

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

 

0
8

SHARED VOTING POWER

 

532,100

 
9

SOLE DISPOSITIVE POWER

 

0
10

SHARED DISPOSITIVE POWER

 

532,100
11

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

532,100
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

 

 

 
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

1.69%
14

TYPE OF REPORTING PERSON*

 

CO

 

 

 

CUSIP NO. 14888D208

 

1

 NAME OF REPORTING PERSON

 

CIDM II, LLC

   
2  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)

 

 

 

 

 

 

 

 

(b)

 

 
3

SEC USE ONLY

 

 

 
4

SOURCE OF FUNDS*

 

 
AF  
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

 

¨

 

 

 
   
6 CITIZENSHIP OR PLACE OF ORGANIZATION  
Delaware  

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

 

0
8

SHARED VOTING POWER

 

 532,100

 
9

SOLE DISPOSITIVE POWER

 

0
10

SHARED DISPOSITIVE POWER

 

532,100
11

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

532,100
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

 

 

 
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

1.69%
14

TYPE OF REPORTING PERSON*

 

OO

 

 

CUSIP NO. 14888D208

 

1

NAME OF REPORTING PERSON

 

 Julian D. Singer

     
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)

 

 

 

 

 

 

 

(b)

 

3

SEC USE ONLY

 

 

4

SOURCE OF FUNDS*

 

AF
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

 

 

 

 
6

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

 

0
8

SHARED VOTING POWER

 

1,312,532
9

SOLE DISPOSITIVE POWER

 

0
10

SHARED DISPOSITIVE POWER

 

1,312,532
11

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

1,312,532
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

 

 

 
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

4.17%
14 TYPE OF REPORTING PERSON*
IN

 

 

CUSIP NO. 14888D208

 

1

NAME OF REPORTING PERSON

 

David S. Oros 

     
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)

 

 

 

 

 

 

 

(b)

 

3

SEC USE ONLY

 

 

4

SOURCE OF FUNDS*

 

PF
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

 

 

 

 
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

 

338,600

 
8

SHARED VOTING POWER

 

0
9

SOLE DISPOSITIVE POWER

 

338,600
10

SHARED DISPOSITIVE POWER

 

0
11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

338,600
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

 

 

 
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

1.08%
14

TYPE OF REPORTING PERSON*

 

IN

 

 

CUSIP NO. 14888D208

 

1

NAME OF REPORTING PERSON

 

Shelly C. Lombard 

     
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)

 

 

 

 

 

 

 

(b)

 

3

SEC USE ONLY

 

 

4 SOURCE OF FUNDS*
 
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

 

 

 

 
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

 

 0

 
8

SHARED VOTING POWER

 

0
9

SOLE DISPOSITIVE POWER

 

0
10

SHARED DISPOSITIVE POWER

 

0
11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

0
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

 

 

 
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

0%
14

TYPE OF REPORTING PERSON*

 

IN

 

 

 

CUSIP NO. 14888D208

 

1

NAME OF REPORTING PERSON

 

Matthew Stecker 

     
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)

 

 

 

 

 

 

 

(b)

 

3

SEC USE ONLY

 

 

4

SOURCE OF FUNDS*

 

 
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

 

 

 

 
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

 

 0

 
8

SHARED VOTING POWER

 

0
9

SOLE DISPOSITIVE POWER

 

0
10

SHARED DISPOSITIVE POWER

 

0
11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

0
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

 

 

 
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

0%
14

TYPE OF REPORTING PERSON*

 

IN

 

 

CUSIP NO. 14888D208

 

1

NAME OF REPORTING PERSON

 

Igor Volshteyn

     
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)

 

 

 

 

 

 

 

(b)

 

3

SEC USE ONLY

 

 

4

SOURCE OF FUNDS*

 

 
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

 

 

 

 
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

 

 0

 
8

SHARED VOTING POWER

 

0
9

SOLE DISPOSITIVE POWER

 

0
10

SHARED DISPOSITIVE POWER

 

0
11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

0
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

 

 

 
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

0%
14

TYPE OF REPORTING PERSON*

 

IN

 

 

CUSIP NO. 14888D208

 

The following constitutes Amendment No. 10 (the “Amendment No. 10”) to the statement on Schedule 13D filed by the undersigned on July 23, 2019 (as amended by Amendment No. 1 filed December 31, 2019, Amendment No. 2 filed January 17, 2020, Amendment No. 3 filed October 25, 2021, Amendment No. 4 filed January 5, 2022, Amendment No. 5 filed January 27, 2022, Amendment No. 6 filed February 23, 2022, Amendment No. 7 filed February 28, 2022, Amendment No. 8 filed March 7, 2022, and Amendment No. 9 filed March 16, 2022, the “Schedule 13D”) relating to the common stock (CUSIP Number: 14888D208), par value $0.001 per share (the “Shares” or the “Common Stock” or the “Shares”), of Catalyst Biosciences, Inc., a Delaware corporation (the “Issuer” or “Company”). This Amendment No. 10 amends the Schedule 13D as specifically set forth herein. Except as specifically provided herein, this Amendment No. 10 does not modify any of the information previously reported in the Schedule 13D.

Item 4.       Purpose of the Transaction

Item 4 is hereby amended to add the following:

As previously disclosed, on March 15, 2022, JDS1, acting pursuant to Section 220 of the Delaware General Corporation Law, delivered a letter to the Issuer demanding the right to inspect certain books, records, and documents of the Issuer and to make and/or receive copies or extracts therefrom (the “JDS1 Inspection Demand”). The books, records, and documents that JDS1 is seeking to inspect pursuant to the JDS1 Inspection Demand relate, in large part, to the record and beneficial ownership of the outstanding Shares. As noted in the JDS1 Inspection Demand, the purpose of the demand is to enable JDS1 to communicate with, and solicit proxies from, the other stockholders of the Issuer with respect to matters relating to their mutual interests as stockholders of the Issuer, including, but not limited to, the composition and structure of the Board of Directors of the Issuer (the “Board”), the election of directors at the Issuer’s 2022 annual meeting of stockholders (the “2022 Annual Meeting”), any other proposals that JDS1 may submit for consideration at the 2022 Annual Meeting, and any other matters that may properly come before the 2022 Annual Meeting.

As of April 20, 2022, more than a month after having delivered the JDS1 Inspection Demand to the Issuer, JDS1 has not received any documents from the Issuer in response to the JDS1 Inspection Demand and has not received any firm commitment from the Issuer as to which of the documents requested by JDS1 would be provided or when any of the documents requested by JDS1 would be provided. Accordingly, on April 20, 2022, JDS1 filed a complaint against the Issuer in the Delaware Court of Chancery seeking to compel the Issuer to produce the documents responsive to the JDS1 Inspection Demand and requesting that the Delaware Court of Chancery order the Issuer to pay reasonable attorneys’ fees and expenses incurred by JDS1 in connection with the JDS1 Inspection Demand and the related litigation.

JDS1 continues to take the necessary steps to prepare for a proxy contest in connection with the 2022 Annual Meeting, JDS1 continues to believe that, given the precipitous decline in the per share price of the Common Stock over the past year, the Board is in urgent need of fresh stockholder representation and that the three nominees JDS1 has proposed for election to the Board at the 2022 Annual Meeting, Shelly C. Lombard, Matthew Stecker, and Igor Volshteyn, can help the Board to explore opportunities to unlock stockholder value. As of the close of business on April 20, 2022, the Common Stock closed at a price of $0.53 per share, which represents an approximately 89.42% decline from the Common Stock’s closing price of $4.98 per share on April 21, 2021. In addition, the Common Stock has spent more than thirty (30) consecutive trading days below $1.00, the latter condition subjecting the Issuer to the risk of being delisted by Nasdaq.

 

 

CUSIP NO. 14888D208

 

Except as set forth in this Schedule 13D or such as would occur upon or in connection with completion of, or following, any of the actions discussed in this Schedule 13D, no Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer’s financial position and strategic direction, actions taken by the Board, the price levels of the Shares, other investment opportunities available to the Reporting Persons, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications with management and/or the Board, engaging in communications with one or more stockholders of the Issuer and others about the Issuer and the Reporting Persons’ investment, making suggestions and/or proposals concerning the Issuer’s capitalization, ownership structure, operations, prospects, business and financial strategies, strategic transactions, assets and liabilities, business and financing alternatives, the structure and composition of the Board, and such other matters as the Reporting Persons may deem relevant to their investment in the Issuer, selling some or all of their Shares in the open market or otherwise, engaging in short selling of or any hedging or similar transaction with respect to the Shares, acquiring additional Shares and/or other equity, debt, notes, other securities, or derivative or other instruments that are based upon or relate to the value of securities of the Issuer, or changing their intention with respect to any and all matters referred to in Item 4.

 

 

CUSIP NO. 14888D208

 

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Dated: April 21, 2022

 

JDS1, LLC

 

 

By: /s/ Julian D. Singer

Name:        Julian D. Singer

Title:          Managing Member

 

 

 

CCUR HOLDINGS, INC.

 

 

By: /s/ Igor Volshteyn

Name:       Igor Volshteyn

Title:         CEO and President

 

 

 

CIDM II, LLC

 

 

By: /s/ Julian D. Singer

Name:        Julian D. Singer

Title:          Managing Member

 

 

 

/s/ David S. Oros

David S. Oros

 

 

 

 

/s/ Julian D. Singer

Julian D. Singer, individually and as attorney-in-fact for Shelly C. Lombard, Matthew Stecker, and Igor Volshteyn

 

Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Catalyst Biosciences Charts.
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Catalyst Biosciences Charts.